Recent News

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Published peer reviewed study show significant improvements in motion and patient-reported measures in adult shoulder replacement patients of all ages.

With the ongoing pandemic affecting in-person meetings and travel, two companies worked to bring surgeon training into the future using virtual reality (VR). Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, presented a training lab for surgeons across the country using Immertec’s proprietary VR platform Medoptic.

William Levine, MD presents the Catalyst CSR™ Total Shoulder System, including two new components, during the 2019 ASES meeting on Saturday, Oct. 19.

Catalyst OrthoScience has raised $12.7 million in an oversubscribed Series C-1 financing round led by River Cities Capital Funds.